| 纯度 | > 85 % SDS-PAGE. |
| 种属 | Human |
| 靶点 | CDC26 |
| Uniprot No | Q8NHZ8 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-85aa |
| 氨基酸序列 | MGSSHHHHHHSSGLVPRGSHMLRRKPTRLELKLDDIEEFENIRKDLETRK KQKEDVEVVGGSDGEGAIGLSSDPKSREQMINDRIGYKPQPKPNNRSSQF GSLEF |
| 预测分子量 | 12 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于CDC26重组蛋白的几篇虚构参考文献及其摘要概括，格式符合要求：
---
1. **《Structural and Functional Analysis of CDC26 in the APC/C Complex》**
*作者：Smith J. et al.*
摘要：本研究通过重组表达人源CDC26蛋白，解析了其在APC/C复合体中的结构作用。实验表明，CDC26通过C端结构域与APC7亚基结合，对复合体的组装及底物泛素化活性至关重要。
2. **《Recombinant CDC26 Facilitates Cell Cycle Regulation in Yeast Models》**
*作者：Li Y. et al.*
摘要：利用重组CDC26蛋白在酵母中重建APC/C功能，发现CDC26缺失导致细胞周期停滞在中期。该研究揭示了CDC26在维持复合体稳定性及驱动有丝分裂进程中的必要性。
3. **《Optimization of CDC26 Recombinant Protein Expression in E. coli》**
*作者：Garcia R. et al.*
摘要：报道了一种高效表达和纯化CDC26重组蛋白的大肠杆菌系统，通过密码子优化和温度调控将蛋白产率提高3倍，为后续功能研究提供可靠工具。
4. **《CDC26 Mutations Disrupt APC/C Activity in Cancer Cells》**
*作者：Wang H. et al.*
摘要：通过重组CDC26突变体分析，发现其某些位点突变会削弱APC/C与底物的结合能力，导致染色体错误分离，提示CDC26异常可能与肿瘤基因组不稳定性相关。
---
注：以上文献为示例性内容，实际研究中需参考真实发表的学术论文。
CDC26 recombinant protein is a key component in the study of cell cycle regulation and ubiquitin-mediated proteolysis. CDC26 (Cell Division Cycle 26) is a conserved subunit of the Anaphase-Promoting Complex/Cyclosome (APC/C), a multi-subunit E3 ubiquitin ligase critical for coordinating the orderly progression of mitosis and the G1 phase. The APC/C targets specific cell cycle regulators, such as securin and cyclins, for degradation via the ubiquitin-proteasome system, ensuring proper chromosomal segregation and exit from mitosis.
Recombinant CDC26 is typically produced using heterologous expression systems (e.g., E. coli, insect cells) to enable biochemical and structural studies. Its recombinant form allows researchers to investigate APC/C assembly, activation mechanisms, and substrate recognition. Structural analyses have shown that CDC26 stabilizes the APC/C complex by interacting with other core subunits like APC3 and APC7. contributing to the overall architecture required for catalytic activity.
Dysregulation of APC/C function, including CDC26-related perturbations, is linked to genomic instability, mitotic errors, and diseases such as cancer. Recombinant CDC26 serves as a tool to explore these pathologies, screen for therapeutic compounds, or engineer mutations to dissect functional domains. Additionally, it aids in studying post-translational modifications (e.g., phosphorylation) that modulate APC/C activity during cell cycle checkpoints.
The development of recombinant CDC26 has advanced our understanding of cell cycle control, offering insights into fundamental biological processes and potential targets for anticancer therapies. Its applications extend to structural biology, drug discovery, and synthetic biology platforms aiming to reconstitute APC/C activity in vitro.
×
